Moleculin Biotech Engages Investors at Virtual 'Top 5 for '25' Conference

Moleculin Biotech, Inc., a late-stage pharmaceutical company (Nasdaq: MBRX), known for its diverse portfolio of drug candidates targeting challenging cancers and viral infections, recently took part in the Virtual Investor "Top 5 for '25" On-Demand Conference. During this event, Walter Klemp, the company's Chairman and CEO, outlined the top five reasons why Moleculin should be on investors’ radar in 2025.

The on-demand video from the conference is now available for public viewing on the Company’s website and provides insights that investors need. This unique platform allows Moleculin to connect with potential investors and industry stakeholders, emphasizing its ongoing commitment to addressing medical challenges faced by patients with hard-to-treat tumors and viruses.

Moleculin Biotech is currently at a pivotal stage in clinical development, particularly with its lead program, Annamycin. This next-generation anthracycline is specifically engineered to overcome multidrug resistance and minimize cardiotoxicity, a common side effect associated with traditional anthracycline drugs. Annamycin is making progress in clinical trials, currently being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The company is launching the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a critical Phase 3 trial that examines the efficacy of Annamycin in combination with cytarabine, known together as AnnAraC. Following a successful Phase 1B/2 study (MB-106) and consultations with the FDA, Moleculin is optimistic about the development path toward potential approval for Annamycin, pending appropriate regulatory feedback.

In addition to Annamycin, Moleculin Biotech is advancing WP1066, an Immune/Transcription Modulator aimed at inhibiting oncogenic transcription factors and promoting natural immune responses. This product holds promise for treating various cancers, including brain tumors and pancreatic cancer. Furthermore, the company is also focused on a range of antimetabolites, such as WP1122, which may be effective against certain viral pathogens as well as additional cancer indications.

Moleculin’s robust pipeline and strategic participation in investor events demonstrate its potential to make significant contributions to oncology and virology therapeutics. For further information about Moleculin Biotech and its innovative solutions, visit www.moleculin.com and follow their updates on platforms like X, LinkedIn, and Facebook.

As the healthcare landscape continues to evolve, Moleculin Biotech remains dedicated to driving research and development efforts that could pave the way for breakthrough therapies in treating difficult diseases. With a solid foundation and collaboration with regulatory bodies, the future appears bright for Moleculin and its formidable therapeutic candidates.